2026-08-26T23:24:59Zhttps://gredos.usal.es/oai/request

oai:gredos.usal.es:10366/1720062026-07-01T00:01:01Zcom_10366_132632com_10366_4512com_10366_3823col_10366_132633

Mora, Elvira Fox, María Laura Lemes, Angelina Velasco, Beatriz Hernández Rivas, Jesús María 2026-06-30T12:21:35Z 2026-06-30T12:21:35Z 2025 Mora, E., Fox, M. L., Lemes, A., Velasco, B., & Hernández-Rivas, J. M. (2025). [Rev. of Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence]. Frontiers in Immunology, 16. https://doi.org/10.3389/FIMMU.2025.1704077. PMID: 41322417; PMCID: PMC12660071. http://hdl.handle.net/10366/172006 10.3389/fimmu.2025.1704077 41322417 1664-3224 [EN]Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES. A scoping review was conducted following the PRISMA Scoping Reviews Checklist to identify real-world evidence of mepolizumab use in HES. In total, 36 references were identified as relevant and selected for review. Overall, 105 patients previously treated with glucocorticoids received mepolizumab at different dosages (range: 100-750 mg), routes of administration (subcutaneous/intravenous), and schedules (every 2-12 weeks). Remission rates were 57.1-76.0%. Most studies reported a range of 71.4-99.1% reduction in mean blood eosinophil counts with mepolizumab treatment. In addition, a glucocorticoid-sparing effect was observed; 85.7% of patients discontinued glucocorticoids after 12 months of mepolizumab administration. Mepolizumab was considered safe and well-tolerated and severe adverse events were rare. Mepolizumab provided clinically significant benefits in patients with HES in a real-world setting. application/pdf eng 25GMO;11 https://doi.org/10.3389/FIMMU.2025.1704077 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Antibodies, Monoclonal, Humanized Hypereosinophilic Syndrome Humans Eosinophils Glucocorticoids Treatment Outcome Glucocorticoids Hypereosinophilic Syndrome Eosinophils Antibodies Treatment Outcome Humans resultado del tratamiento humanos síndrome hipereosinofílico eosinófilos glucocorticoides anticuerpos Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Frontiers in immunology 16 1704077